Find policies, billing codes, payers, states, and providers

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 114 encompasses inpatient orbital procedures without Complication or Comorbidity or Major Complication or Comorbidity, covering surgical management of orbital injuries and noncomplex orbital operations. Precise coding and documentation matter because assignment to this Diagnosis-Related Group affects the Medicare bundled payment level for the hospital.

Customize your policy alerts

Sign up for Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 114 Overview

DRG 114 covers inpatient orbital procedures without Complication or Comorbidity or Major Complication or Comorbidity, including surgical interventions on the orbit such as repair of orbital fractures, decompression for noncomplex indications, and exploration or drainage procedures when no significant comorbid conditions are coded. This Diagnosis-Related Group groups cases by clinical similarity and resource use so hospitals receive a bundled payment under Medicare Severity Diagnosis-Related Group weighting. It matters for Medicare payment because the absence of Complication or Comorbidity and Major Complication or Comorbidity places these admissions in a lower payment tier than more complex orbital cases. Accurate coding of diagnoses and procedures determines assignment to this Diagnosis-Related Group and therefore influences inpatient reimbursement.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

Customize your policy alerts

Sign up for Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 114 Overview

National Payment Rates

Across payers the observed rate range runs roughly from $370 up to $44K, with mean benchmark values spanning about $11K to $22K across major payers. The widest spread appears between Anthem (min $390, max $44K) and other payers with much narrower upper bounds, indicating notable variation in allowed amounts. See the table and chart below for payer-specific quartiles and distributions.

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment (avg_tot_pymt_amt), average submitted covered charges (avg_submtd_cvrd_chrg), average Medicare payment amount (avg_mdcr_pymt_amt), and total discharges (tot_dschrgs) for DRG 114. Values in the CMS table are presented in aggregated form for national-level Medicare activity.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$14K	$77K	$12K	75

Patient Population

The DRG 114 population skews toward a mixed-age cohort but with substantial representation among Medicare-age beneficiaries given its inclusion in Medicare inpatient claims reporting. Commercial/ private payers (e.g., Aetna, Cigna, BCBS, Anthem) also cover working-age adults, so the payer mix typically includes both Medicare-age and working-age patients. Overall, the population is not exclusively Medicare-age nor exclusively working-age but spans both groups.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska, DRG 114 shows a payer range from $21K to $33K across the reported payers, with Cigna at the high end and Anthem and Blue Cross Blue Shield at the low end. The state exhibits a noticeable upward deviation for Cigna versus the national payer means displayed. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $33K); Lowest payers: Anthem and BCBS (each mean $21K).
Cigna’s mean ($33K) in Alaska is notably above the national payer means shown, indicating a meaningful premium relative to the national context.
Anthem and Blue Cross Blue Shield are clustered at the state floor ($21K), creating a wide state range from $21K to $33K.

Clinical Trials

Prospective randomized or controlled studies of acute surgical techniques and perioperative management for orbital fractures and acute orbital decompression: these trials compare approaches such as different orbital implant materials, surgical access routes, or timing of repair in patients admitted urgently for traumatic orbital floor or wall fractures and compressive optic neuropathy. The objective is to determine which techniques reduce immediate complications (e.g., diplopia, enophthalmos, vision loss) and shorten LOS; results are relevant to surgeons, hospital administrators, and payers because optimized operative pathways can lower reoperation rates and resource use.
Comparative effectiveness studies of minimally invasive versus open orbital procedures for benign orbital masses and inflammatory orbital disease: observational cohort or pragmatic randomized studies evaluate functional and quality-of-life outcomes, complication rates, and need for readmission in adult patients undergoing endoscopic or transconjunctival approaches versus traditional external approaches for tumor excision or orbital biopsy. These studies address which approaches offer similar disease control with fewer hospital days and lower complication-related costs, informing procedure selection, care pathways, and reimbursement decisions.
Post-discharge outcomes and health services research focusing on readmissions, functional vision, and long-term rehabilitation needs after orbital surgery: longitudinal registry-based or prospective cohort studies track patients discharged after orbital procedures without major comorbidities to measure rates of late complications (infection, persistent diplopia, visual decline), utilization of outpatient strabismus services or prosthetics, and patient-reported visual function. This research helps payers and case managers predict post-acute care needs, allocate resources for outpatient follow-up or rehabilitation, and develop bundled payment models tied to longer-term outcomes rather than only the index hospitalization.

Related Codes

113-ORBITAL-PROCEDURES-WITH-CC-MCC

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

121-ACUTE-MAJOR-EYE-INFECTIONS-WITH-CC-MCC

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

122-ACUTE-MAJOR-EYE-INFECTIONS-WITHOUT-CC-MCC

Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

124-OTHER-DISORDERS-OF-THE-EYE-WITH-MCC-OR-THROMBOLYTIC-AGENT

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

National Payment Rates

Mean Rates by Payer — National — DRG 114

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$14K	$77K	$12K	75

Patient Population

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 114

Key Insights for Alaska

Highest payer: Cigna (mean $33K); Lowest payers: Anthem and BCBS (each mean $21K).
Cigna’s mean ($33K) in Alaska is notably above the national payer means shown, indicating a meaningful premium relative to the national context.
Anthem and Blue Cross Blue Shield are clustered at the state floor ($21K), creating a wide state range from $21K to $33K.

Clinical Trials

Prospective randomized or controlled studies of acute surgical techniques and perioperative management for orbital fractures and acute orbital decompression: these trials compare approaches such as different orbital implant materials, surgical access routes, or timing of repair in patients admitted urgently for traumatic orbital floor or wall fractures and compressive optic neuropathy. The objective is to determine which techniques reduce immediate complications (e.g., diplopia, enophthalmos, vision loss) and shorten LOS; results are relevant to surgeons, hospital administrators, and payers because optimized operative pathways can lower reoperation rates and resource use.
Comparative effectiveness studies of minimally invasive versus open orbital procedures for benign orbital masses and inflammatory orbital disease: observational cohort or pragmatic randomized studies evaluate functional and quality-of-life outcomes, complication rates, and need for readmission in adult patients undergoing endoscopic or transconjunctival approaches versus traditional external approaches for tumor excision or orbital biopsy. These studies address which approaches offer similar disease control with fewer hospital days and lower complication-related costs, informing procedure selection, care pathways, and reimbursement decisions.
Post-discharge outcomes and health services research focusing on readmissions, functional vision, and long-term rehabilitation needs after orbital surgery: longitudinal registry-based or prospective cohort studies track patients discharged after orbital procedures without major comorbidities to measure rates of late complications (infection, persistent diplopia, visual decline), utilization of outpatient strabismus services or prosthetics, and patient-reported visual function. This research helps payers and case managers predict post-acute care needs, allocate resources for outpatient follow-up or rehabilitation, and develop bundled payment models tied to longer-term outcomes rather than only the index hospitalization.

Related Codes

113-ORBITAL-PROCEDURES-WITH-CC-MCC

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

121-ACUTE-MAJOR-EYE-INFECTIONS-WITH-CC-MCC

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

122-ACUTE-MAJOR-EYE-INFECTIONS-WITHOUT-CC-MCC

Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

124-OTHER-DISORDERS-OF-THE-EYE-WITH-MCC-OR-THROMBOLYTIC-AGENT

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

Sign up for Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 114 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

Sign up for Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 114 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References